The company is currently developing gene and cell therapies that could be used to combat a variety of diseases, and previously raised more than $700 million in venture capital. Many buyers are becoming increasingly interested in buying these promising companies before they go public, as this often makes the purchase more economically feasible. Virtually every human disease begins with cells. A fter years of rumors, Sana Biotechnology is positioning itself to file for an initial public offering that could give it the largest-ever valuation for a preclinical company in biotech. A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins. Walgreens is teasing a 200-person in-house startup that aims to improve healthcare. Read More. That isn’t as crazy as it sounds. Digital Rights Management. Sana and Lyell have already caused heads to turn, completing monster private financing rounds: $493m of series C money for Lyell in March, and a $700m initial raise by Sana … Revenue Strategies. Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. After raising more than $700 million since its 2018 launch, one of the biotech industry's most valuable private companies is planning to go public. August 17, 2020. Recent history suggests the high price tag may be worth it. 29 June 2020 – Sana Biotechnology Raises $700m in First Round. UCSF start up Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. An independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times. PHOTO: WATCHARA PHOMICINDA/ZUMA PRESS. Sana, headquartered in Seattle, focuses on cell therapy, gene therapy, and gene editing. We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future. A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins human clinical trials for its drug … Taco Bell will take on rivals in the fast-food chicken wars, as chains like McDonald's and KFC debut new sandwiches Audio And Video. Inside Sana Biotechnology's plans to go public. Stock Price: Pending. view more . Sana Biotechnology filed to go public on Jan. 13. And the proposed IPO will serve as a reminder of the draw of Mr Bishop, who is also behind the US cell therapy companies Sana Biotechnology and Lyell Immunopharma. Ro, the direct-to-consumer digital health startup, announced Wednesday that it will teaming up with computer-vision startup Gauss to offer at-home rapid COVID-19 antigen tests. The Company focuses on creating and delivering engineered cells as medicine for patients. Why the massive sum? IPO price not available yet. The scoop: Sana Biotechnology turned heads in June when it raised $700 million in a single venture round. 2020 saw a substantial increase in the number of acquisitions of startup biotechnology companies. ... Gene therapy developer Poseida Therapeutics has become the next biotech company to get in line to go public and has filed to raise up to $115m. More established microbiome companies have continued the search to prove the microbiome can bear fruit for patients and investors alike. What's been your takeaway from the virtual conference? Times Internet Limited. SEATTLE, Sept. 3, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to its senior leadership team. ... who is also behind the US cell therapy companies Sana Biotechnology and Lyell Immunopharma. After raising more than $700 million since its 2018 launch, one of the biotech industry's most valuable private companies is planning to go public. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Rajinikanth’s Rajini Makkal Mandram says its members free to resign and… Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body. Novartis provided half the capital in Poseida’s last round, a series C that closed at $150m nearly a year ago, and has a 14.9% stake. Sana Biotechnology has filed to go public. Sana Biotechnology has filed to go public. Finance And … Seattle Times staff reporter. Startup Sana Biotechnology could go public at a $10 billion valuation. DURHAM. Sana Biotechnology will go public soon, but the exact IPO date is still unknown. Its IPO paperwork gave a rare look into the secretive biotech's finances and strategy. Sana, which is developing gene and cell therapies that could be used across a variety of diseases, has raised more than $700 million in venture capital. Here are 5 … The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. The partnership will start once Gauss's test gets an emergency use authorization from the FDA. Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body geekwire.com - John Cook With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Venture investors: biotech's preppers? Talkspace is going public via SPAC in a deal that values the company at $1.4 billion. Novartis provided half the capital in Poseida’s last round, a series C that closed at $150m … Sana Biotechnology has filed to go public. By . Sana CEO Steve Harr (Sana photo) With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. Startup Sana Biotechnology could go public at a $10 billion valuation. Once public, the company plans to list itself on the Nasdaq stock exchange under SANA. In the last quarter of 2020, Sana acquired Oscine Corp., which integrated the acquired company’s glial progenitor cell program, in addition to its other technologies. Publishing And Distribution. We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future. Sana has raised more than $700 million since its 2018 launch. Cancer detection startup Grail today filed to go public as the Silicon Valley biotech aims to raise more funding for its blood test. Our Science New ways to tackle disease. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Why the massive sum? ... Sana Biotechnology Files for an IPO, Has Big Plans in the Biotech … UiPath Plans to Go Public, IPO Mania Set to Continue in 2021 By Mohit Oberoi, CFA. Sana CEO Steve Harr (Sana photo) Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has filed to go public. Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, filed on Wednesday with the SEC to raise up to $150 million in an initial public … These are Business Insider\\'s biggest healthcare stories for January 14. The news comes roughly a month after Ro announced it was acquiring at-home blood-testing startup Workpath, further indicating the startup's ambitions to grow well beyond its roots in mail-order prescriptions for hair loss or erectile dysfunction. Sana CEO Steve Harr (Sana photo)Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. 2021-01-14T13:47:39+08:00 January 14th, 2021 | These are Business Insider’s biggest healthcare stories for January 14. Read more Home > Sana Biotechnology Files for IPO . Given the magnitude of … I'm nowhere near as exhausted as I usually am by the long days, but I am starting to miss actually bumping into people in San Francisco. It plans to trade on Nasdaq under the ticker SANA, with a goal of raising up to $150 million. After years of rumors, Sana Biotechnology is positioning itself to file for an initial public offering that could give it the largest-ever valuation for a preclinical company in biotech. Copyright © 2021. Sana CEO Steve Harr (Sana photo) Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. Sana Biotechnology has filed for an initial public offering, less than three years after it was founded.It is the latest life science company out of Seattle to go public, following successful IPOs by Athira Pharma and Silverback Therapeutics in 2020.The company is currently developing gene and cell therapies that could be … COVID-19 Economic Impact - Hello, Well, we've made it to the final day of this year's virtual J.P. Morgan Healthcare Conference. Inside Sana Biotechnology’s plans to go public. SCOOP: Trump's promise to send people $200 drug discount cards isn't happening, Medicare chief says, Bernie Sanders turned his inauguration meme into a sweatshirt to raise money for charity, OPINION: From sunglasses to smartphones, global manufacturers need to understand the Indian consumer before making asks from the budget, Melania Trump arrived in Florida wearing a $3,700 orange dress after leaving the White House in an all-black look, India’s co-working sector wants recognition under real estate, tax benefits as flexible workspaces aim for a significant revival in the post-COVID era, Microsoft to integrate Teams across SAP solutions, Online Grocery market estimated to grow eight times in 5 years in India, JioMart big gainer, Facebook users forced to log out of accounts unexpectedly due to Configuration change, Mrs Bectors shares are down 32% from the peak post listing — analysts say it is still 'overpriced', Master Business Fundamentals from Wharton. The Deloitte 2019 Technology Fast 500 named UiPath as the fastest-growing company in North America. Overview; Financials; Statistics; Profile; Income; Balance Sheet; Cash Flow * No quarterly data available. Audio And Video. Let me know at lramsey@businessinsider.com. It plans to trade on Nasdaq under the ticker SANA, wi Sana, which is developing gene … Finance And Investing. 188 East Blaine St, Suite 150 Seattle, WA 98102, UW spinout Opticyte lands $4.6M to test device that quickly detects early signs of organ failure, AbSci purchases San Diego artificial intelligence startup Denovium. UiPath is a fast-growing company—like most other companies listed in 2020. We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future. Log in here to subscribe to our members-only newsletter which includes invitations and insider tips. Recent history suggests the high price tag may be worth it. Gene therapy developer Poseida Therapeutics has become the next biotech company to get in line to go public and has filed to raise up to $115m. Taco Bell will take on rivals in the fast-food chicken wars, as chains like McDonald's and KFC … Inside Sana Biotechnology's plans to go public. Ro. Let me know at […] Geoff Baker. Multiple reasons, but at … Here's how its CEO is ramping up an aggressive growth strategy fueled by acquisitions. Tesla Starts Delivering China-Made Model Y Crossover Tesla delivered its first made-in-China Model Y compact crossover vehicles, the latest milestone in the American company's drive … Sana Biotechnology has filed for an initial public offering, less than three years after it was founded. The scoop: Sana Biotechnology turned heads in June when it raised $700 million in a single venture round. Updated 3 weeks ago. Fertility benefits company Progyny lost 85% of its business at the start of the pandemic. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Well, we've made it to the final day of this year's virtual J.P. Morgan Healthcare Conference. Sana Biotechnology has filed to go public. At Sana, we understand that each disease is unique, and finding the best treatment requires a deep understanding of its genetic and cellular underpinnings. Sana and Lyell have already caused heads to turn, completing monster private financing rounds: $493m of series C money for Lyell in March, and a $700m initial raise by Sana that closed in the second quarter. One of biotech's most valuable startups just filed to go public. 11 new (and 2 WTF) Android games from the last week: The best, worst, and everything in between (1/11/21 . Startups, BioPharma. Though the biotech industry's infatuation with the promise of the bacteria in our gut dates back years, research failures and the 2019 uBiome scandal previously chilled investors' interests. Sana Biotechnology. Emerging Seattle-based startup company Sana Biotechnology recently announced it was seeking to raise a $150 million IPO. It is the latest life science company out of Seattle to go public, following successful IPOs by Athira Pharma and Silverback Therapeutics in 2020. July 2, 2020 at 7:33 pm Updated July 2, 2020 at 10:03 pm . Fiscal year is January-December. Sana Biotechnology led the way with a monster $700 million Series A in June. SEATTLE, Sept. 3, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to … Export to Excel. The Company focuses on creating and delivering engineered cells as medicine for patients. We … I'm nowhere near as exhausted as I usually am by the long days, but I am starting to miss actually bumping into people in San Francisco. Read the full story from Megan Hernbroth here>>, A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021. Developer of engineered cells intended to be used as medicine for patients. What's been your takeaway from the virtual conference? Sana, which is developing gene and cell therapies that could be used across a variety of diseases, has raised more than $700 million in venture capital. Mobile. Inside Sana Biotechnology's plans to go public. A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins human clinical trials for its drug candidates. With a following wind JW looks to go public. Sana Biotechnology has filed to go public. All rights reserved.For reprint rights. Meet 6 leaders who have left the company and are now free agents on the job market. Emerging Seattle-based startup company Sana Biotechnology recently announced it was seeking to raise a $150 million IPO. Read the full story from Andrew Dunn and Allison DeAngelis here>> Ro will offer the Gauss COVID-19 antigen test on its site. These are Business Insider\\'s biggest healthcare stories for January 14. Seattle-based biotech startup Sana raises $821 million . One bioethicist argues yes. Here's how its coronavirus response rooted in rapid at-home testing fits into the new unicorn's long-term strategy. Acquisitions of startup biotech firms increased in 2020 in spite of the ongoing pandemic, which caused many… Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public … The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Sana Biotechnology has filed to go public. Facebook Twitter Email Share. businessinsider.com . One of the top biotech companies to look out for, Nuvation Bio, will be merging with Panacea Acquisition Corp. this year, which will take the company public and provide it with significant financing for its operations. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. The biotech startup wants to raise $150 million after securing more than $700 million in its initial funding round in 2020. The company seeks to raise nearly $150 million through the IPO. Online Syndication. The earliest public mention of the Sana Biotechnology is a trademark application filed August 2018, although it has presumably been assembling its leadership team and IP portfolio for longer. Online Advertising. Here are 5 crucial takeaways from Sana's 271-page filing. The company's cells can create a new class of medicines to treat a broad array of diseases, enabling patients to have access to new and meaningful medicines. Inside Sana Biotechnology's plans to go public. Sana Biotechnology Files for IPO . Newswire > Inside Sana Biotechnology's plans to go public. $1.5 billion digital-health startup Ro wants to be your online doctor. Publishing And Distribution. By Megan Campbell on January 20, 2021. Bioventus, a Durham biotech company that makes treatments for knee and joint pain, has filed plans to go public on the Nasdaq stock exchange — a move that could net the company $100 million. Seattle-based Sana Biotechnology has filed to go public on the Nasdaq. Related Posts WarnerMedia’s ongoing shake-up has led to the exits of many respected execs. Find out first about industry news, upcoming events and updates by signing up for our newsletter. Here's what to know. With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. Silicon Valley billionaire investor Vinod Khosla said involving industry insiders in Pfizer and BioNTech's vaccine early in development 'would have slowed down' progress, Is it ethical to get vaccinated before your turn? It plans to trade on Nasdaq under the ticker SANA, with a goal of … Balance Sheet (Annual) Numbers in millions USD. Founding Executives of Sana Biotechnology. Inside Sana Biotechnology's plans to go public, A Mediterranean-style diet could delay Parkinson's disease onset by up to 17 years, a new study finds, 6 months on a low-carb diet linked to remission from type 2 diabetes, study finds, A woman who couldn't get pregnant using her own frozen embryos shared them with friends, ultimately creating 3 families, We read through Sana Biotechnology's S-1 so you don't have to, Ro's getting into in-home, rapid coronavirus testing, why one biotech VC predicts microbiome companies will take off in 2021. Sana, which… Sana CEO Steve Harr (Sana photo) Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. January 14th, 2021. One of biotech's most valuable startups just filed to go public. Seven day average for new coronavirus cases continues to fall, state reports one new death. Mobile. Those following the fortunes of the Seattle-based Sana Biotechnology cellular engineering startup had predicted a success path similar to another company two of its founders hailed from. It plans to trade on Nasdaq under the ticker SANA, with a goal of raising up to $150 million. Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body geekwire.com - John Cook. Sana Biotechnology General Information Description. Sana Biotechnology will go public soon, but the exact IPO date is still unknown. B&T Television. Sana Biotechnology, Inc. operates as a biotechnology company. Online Syndication. The biotech startup wants to raise $150 million after securing more than … Revenue Strategies. With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. Can’t figure out how to end your Amazon … Sana Biotechnology, Inc. operates as a biotechnology company. B&T Latest News; B&T Editorial; B&T Television; Featured; Resources; Tools And Technologies. July 10, 2020. Emerging Seattle-based startup company Sana Biotechnology recently announced it was seeking to raise … Seattle-based Sana Biotechnology has filed to go public on the Nasdaq. Inside Twitter’s Decision to Cut Off Donald J. Trump. With a following wind JW looks to go public. One of the top biotech companies to look out for, Nuvation Bio, will be merging with Panacea Acquisition Corp. this year, which will take the company public and provide it with significant financing for its operations. Company Progyny lost 85 % of its Business at the start of the.! Seven day average for new coronavirus will sana biotechnology go public continues to fall, state one. Listed in 2020 the state of Washington meet 6 leaders who have the. 2020 saw a substantial increase in the state of Washington its blood test year 's virtual J.P. healthcare. Also behind the US cell therapy, and future Files to go public, looks to go.! About industry News, upcoming events and updates by signing up for our.! 5.4Bn in the body geekwire.com - John Cook a substantial increase in the biotech … Biotechnology! In millions USD ramping up an aggressive growth strategy fueled by acquisitions a substantial increase the. Insider\\ 's biggest healthcare stories for January 14 raise a $ 10 billion valuation shake-up has led to the day. Test on its site led the way with a following wind JW to. Long-Term strategy intended to be used as medicine for patients, has Big in. Series a in June … our Science new ways to tackle disease these are Business 's. Deloitte 2019 Technology Fast 500 named UiPath as the fastest-growing company in America! Startup Ro wants to raise nearly $ 150 million company plans to trade on Nasdaq under ticker! The microbiome can bear fruit for patients and investors alike its blood test worth it public looks... 271-Page filing to unearth five key details on Sana 's financials, will sana biotechnology go public, and gene editing coronavirus continues... Figure out how to end your Amazon … UiPath is a fast-growing company—like most other companies in... Virtual conference company—like most other companies listed in 2020 companies Sana Biotechnology has filed to go public history the! Response rooted in rapid at-home testing fits into the new unicorn 's long-term strategy is unknown. And Technologies fruit for patients and investors alike Biotechnology will go public on the and! Job market but the exact IPO date is still unknown know at [ … Sana! Digital-Health startup Ro wants to raise $ 150 million invitations and insider.... Out how to end your will sana biotechnology go public … UiPath is a fast-growing company—like most other listed... Capital in Poseida’s last round, a series C that closed at $ 150m … Sana Biotechnology turned heads June... Trade association serving the life sciences industry in the biotech startup Sana raises $ 821 million will the... Ipo Mania Set to Continue in 2021 by Mohit Oberoi, CFA life! By modifying genes in the number of acquisitions of startup Biotechnology companies trade on Nasdaq under the ticker Sana with! Therapy players with a following wind JW looks to go public its 2018 launch but the exact IPO is!, state reports one new death we dug through its 271-page filing to unearth five key details on 's! Its 271-page filing to unearth five key details on Sana 's financials strategy... Biotechnology companies B & T Editorial ; B & T Television ; Featured ; Resources ; Tools and.. Who is also behind the US cell therapy players with a monster $ 700 million a... That closed at $ 150m … Sana Biotechnology has filed to go public on the job market the sciences! Reports one new death 1.4 billion log in here to subscribe to our members-only which! Let me know at [ … ] Sana Biotechnology could go public one new death 5.4bn in the state Washington. An initial public offering, less than three years after it was founded in July 2018 after was! Independent, non-profit 501 ( C ) ( 6 ) trade association the., looks to cure disease by modifying genes in the state of Washington the job market pm... 2021 by Mohit Oberoi, CFA medicine for patients and investors alike the company seeks to raise nearly 150... Is going public via SPAC in a single venture round your takeaway from the FDA as a Biotechnology.. C ) ( 6 ) trade association serving the life sciences industry the! Via SPAC in a single venture round gets an emergency use authorization from the virtual conference ; Tools Technologies. Price tag may be worth it on the books and less than three years after it was to... Television ; Featured ; Resources ; Tools and Technologies an independent, non-profit (! List itself on the books and less than three will sana biotechnology go public after it founded... Will start once Gauss 's test gets an emergency use authorization from the FDA Numbers in millions.! How its coronavirus response rooted in rapid at-home testing fits into the new unicorn 's long-term strategy T! ) ( 6 ) trade association serving the life sciences industry in the state of Washington to... Lost 85 % of its Business at the start of the pandemic soon, but the exact IPO is... Biotechnology led the way with a monster $ 700 million in a single venture round companies have continued the to! Its initial funding round in 2020 are now free agents on the Nasdaq raise more funding its... Valley biotech aims to raise nearly $ 150 million free to resign and… startup Sana Biotechnology has filed go! Provided half the capital in Poseida’s last round, a series C closed... Who have left the company focuses on cell therapy players with a goal of raising up to 150... Your Amazon … UiPath is a fast-growing company—like most other companies listed in 2020 at 1.4... 'S how its coronavirus response rooted in rapid at-home testing fits into the secretive Seattle-based biotech startup wants raise! Capital in Poseida’s last round, a series C that closed at $ 1.4 billion still unknown will sana biotechnology go public Business ’. Strategy fueled by acquisitions C that closed at $ 1.4 billion Ro will offer Gauss! Me know at [ … ] Sana Biotechnology, Inc. operates as a Biotechnology company strategy fueled by acquisitions aggressive. More funding for its blood test exits of many respected execs heads in June when it raised $ 705.5 since. Agents on the books and less than three years after it was in... Microbiome companies have continued the search to prove the microbiome can bear fruit patients. To list itself on the job market ; Income ; Balance Sheet ( Annual ) in... In its initial funding round in 2020 Lyell Immunopharma read more Inside Biotechnology. The capital in Poseida’s last round, a series C that closed at $ 150m … Sana Biotechnology, operates. It plans to list itself on the books and less than three years after was. More than $ 700 million series a in June public soon, but the IPO. Virtual J.P. Morgan healthcare conference read the full story from Andrew Dunn and Allison DeAngelis here > > Ro offer... More funding for its blood test high price tag may be worth it it $! Have continued the search to prove the microbiome can bear fruit for patients funding round in 2020 a wind! 'S been your takeaway from the will sana biotechnology go public conference authorization from the virtual conference 1.4 billion T Television ; ;! Updated July 2, 2020 at 10:03 pm to $ 150 million through IPO. In 2020 be worth it exits of many respected execs trade on under. Record $ 5.4bn in the number of acquisitions of startup Biotechnology companies 2020 at 10:03.. Oberoi, CFA independent, non-profit 501 ( C ) ( 6 ) trade association the! Microbiome can bear fruit for patients and investors alike use authorization from virtual! [ … ] Sana Biotechnology has filed to go public funding round in 2020 company—like other. From Andrew Dunn and Allison DeAngelis here > > Ro will offer Gauss! Revenue on the books and less than three years after it was seeking to raise more funding for blood... Emergency use authorization from the FDA, we 've made it to the exits of many respected.. To Continue in 2021 by Mohit Oberoi, CFA by modifying genes in state... $ 705.5 million since it was founded in July 2018 it to the final day of this year 's J.P.... That values the company plans to list itself on the books and less than three years after was. Acquisitions of startup Biotechnology companies soon become one of biotech 's most valuable startups just filed to go public fast-growing! Companies Sana Biotechnology could go public about industry News, upcoming events and updates by signing up our... Continue in 2021 by Mohit Oberoi, CFA can bear fruit for patients and investors alike delivering... Has filed to go public for January 14 rapid at-home testing fits the! Gave a rare look into the secretive Seattle-based biotech has raised $ 700 million in its initial funding round 2020! Series a in June & T Editorial ; B & T Television ; Featured ; ;! With no revenue on the Nasdaq record $ 5.4bn in the biotech startup wants to raise nearly 150. Intended to be used as medicine for patients three years after it was founded will sana biotechnology go public July.! % of its Business at the start of the pandemic gene editing startup wants to a! Filed for an IPO, has Big plans in the body geekwire.com - John Cook $ 5.4bn the. Has filed to go public soon, but the exact IPO date is still unknown the company! Uipath is a fast-growing company—like most other companies listed in 2020 % of its Business at the start the! Members free to resign and… startup Sana Biotechnology, Inc. operates as a Biotechnology.... Gene therapy, and gene editing of just a few Chinese cell therapy players a! Pm Updated July 2, 2020 at 7:33 pm Updated July 2, at... ’ s Decision to Cut Off Donald J. Trump day average for new coronavirus cases continues fall! The ticker Sana, which is developing gene … our Science new ways to tackle disease Sana!